Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POMALYST vs POMALIDOMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b FGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
Multiple myeloma (in combination with dexamethasone) in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy,AIDS-related Kaposi sarcoma (in patients with AIDS-related Kaposi sarcoma who have failed highly active antiretroviral therapy [HAART] or are intolerant to HAART)
Multiple myeloma, relapsed or refractory (in combination with dexamethasone),Multiple myeloma, maintenance therapy post-autologous stem cell transplant,AIDS-related Kaposi sarcoma (off-label),Primary effusion lymphoma (off-label)
4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
Terminal elimination half-life is approximately 7.5 hours in patients with multiple myeloma, allowing for once-daily dosing without accumulation at steady state.
Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment.
Pomalidomide is primarily metabolized by cytochrome P450 (CYP) 1A2 and CYP3A4. It also undergoes hydroxylation and subsequent glucuronidation. Minor pathways include CYP2C19 and CYP2D6.
Primarily metabolized by CYP1A2 and CYP3A4; undergoes glucuronidation via UGT1A8.
Approximately 73% of radiolabeled pomalidomide is excreted in urine (primarily as metabolites, with <2% as unchanged drug) and 15% in feces. Renal clearance is the major elimination pathway.
Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal).
33% bound to human plasma proteins, predominantly to albumin.
12-44% bound to albumin and alpha-1-acid glycoprotein; mean ~30%.
Apparent volume of distribution is approximately 120 L (1.7 L/kg for a 70 kg individual), indicating extensive tissue distribution beyond plasma volume.
62-138 L (approx 0.8-1.7 L/kg); indicates extensive tissue distribution.
Oral bioavailability is approximately 73% (range: 66-81%). Administration with a high-fat meal decreases Cmax by 36% and AUC by 26% relative to fasting; therefore, take on an empty stomach.
Oral: 73% (range 56-85%); high fat meal reduces AUC by 13% but no significant effect.
For Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: reduce dose to 3 mg once daily; Cr Cl <30 m L/min: not recommended (no dose established).
Cr Cl 30-59 m L/min: 3 mg once daily. Cr Cl <30 m L/min: 2 mg once daily. Not recommended if Cr Cl <15 m L/min or requiring dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 3 mg once daily; Child-Pugh C: reduce dose to 2 mg once daily.
Child-Pugh A: 4 mg once daily. Child-Pugh B: 2 mg once daily. Child-Pugh C: 1 mg once daily.
Safety and efficacy not established in pediatric patients; no standard dosing.
Safety and efficacy not established; no recommended dosing.
No specific dose adjustment based on age alone; monitor for toxicity and adjust based on renal function as per adult recommendations.
No specific dose adjustment; monitor for increased toxicity (e.g., myelosuppression, neurotoxicity) due to age-related organ function decline.
WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM. Pomalidomide is contraindicated in pregnant women because it can cause severe birth defects or death to an unborn baby. Females of reproductive potential must avoid pregnancy during treatment and for at least 4 weeks after the last dose. Pomalidomide is only available through a restricted distribution program called the POMALYST REMS program. Additionally, pomalidomide significantly increases the risk of venous and arterial thromboembolism (including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke). Thromboprophylaxis is recommended.
WARNING: EMBRYO-FETAL TOXICITY, VENOUS AND ARTERIAL THROMBOEMBOLISM, HEPATOTOXICITY, and INCREASED MORTALITY IN MULTIPLE MYELOMA. Pomalidomide is contraindicated in pregnant women due to teratogenicity. Thromboembolic events (DVT, PE, MI, stroke) are increased. Hepatotoxicity may be severe. In multiple myeloma clinical trials, pomalidomide/dexamethasone was associated with increased mortality in patients with high-risk cytogenetics (del 17p, t(4;14), t(14;16)).
Embryo-fetal toxicity: Can cause fetal harm; females of reproductive potential must use effective contraception and avoid pregnancy. Males should avoid donating sperm.,Thromboembolism: Increased risk of venous and arterial thromboembolic events; thromboprophylaxis recommended.,Hematologic toxicity: Neutropenia and thrombocytopenia are common; monitor blood counts regularly.,Hepatotoxicity: Can cause elevated liver enzymes and hepatic failure; monitor liver function tests.,Cardiac toxicity: Increased risk of heart failure, myocardial infarction, and atrial fibrillation.,Hypersensitivity reactions: Including angioedema, Stevens-Johnson syndrome, and toxic epidermal necrolysis; discontinue if severe reaction occurs.,Tumor lysis syndrome: Monitor patients at risk.,Interference with oral contraceptives: May reduce efficacy of oral contraceptives; consider additional non-hormonal contraception.
Embryo-fetal toxicity (must use contraception); venous/arterial thromboembolism (consider prophylaxis); hepatotoxicity (monitor LFTs); increased mortality in high-risk multiple myeloma; hematologic toxicity (neutropenia, thrombocytopenia); cardiac toxicity (arrhythmias, heart failure); severe cutaneous reactions; tumor lysis syndrome; renal impairment; fetal risk during pregnancy; avoid use in patients with prior hypersensitivity to thalidomide analogs.
Pregnancy,Hypersensitivity to pomalidomide or any component of the formulation
Pregnancy (absolute); women of childbearing potential not using effective contraception; men not using condoms during sexual activity with pregnant or non-pregnant women; hypersensitivity to pomalidomide or thalidomide analogs; prior severe dermatologic reactions to pomalidomide.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction. No specific dietary restrictions otherwise; take with or without food. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid alcohol due to increased risk of liver toxicity.
Avoid grapefruit juice and grapefruit products. Take with water, not with food to reduce nausea.
Pomalidomide is an immunomodulatory drug (IMi D) structurally related to thalidomide, a known human teratogen. It is contraindicated in pregnancy due to high risk of severe birth defects or embryo-fetal death. Fetal exposure during any trimester can cause major congenital malformations, including limb defects, craniofacial anomalies, and cardiovascular abnormalities. Use in females of reproductive potential requires negative pregnancy testing before treatment, and use of two effective contraceptive methods during therapy and for 4 weeks after discontinuation. Pregnancy testing frequency: weekly during first month, then every 2-4 weeks if regular cycles, or every 2 weeks if irregular cycles.
First trimester: High risk of severe birth defects (e.g., limb anomalies, neural tube defects) due to potent teratogenicity; absolutely contraindicated. Second/third trimester: Risk of fetal harm persists; no safe level established; discontinue if possible.
It is unknown whether pomalidomide is excreted in human milk. Due to the potential for serious adverse reactions in breastfeeding infants, women should not breastfeed during treatment with pomalidomide. No M/P ratio is available.
No data on M/P ratio; excreted in animal milk; potential for serious adverse reactions in infant; breastfeeding contraindicated during therapy and for at least 7 days after last dose.
Pomalidomide is contraindicated in pregnancy; no dose adjustments are applicable because use during pregnancy is not recommended. If exposure occurs, the manufacturer recommends immediate discontinuation and referral to a teratology specialist. No pharmacokinetic studies on pregnancy-related dose adjustments exist.
No specific dose adjustments in pregnancy due to contraindication; pharmacokinetic changes (e.g., increased clearance) theoretically require higher doses if used, but teratogenicity prohibits use; avoid exposure entirely.
Pomalidomide is an immunomodulatory drug used in multiple myeloma after prior therapies including lenalidomide and bortezomib. Requires baseline and periodic CBCs, liver and renal function tests. High risk for venous thromboembolism; prophylaxis with aspirin or anticoagulation recommended. Contraindicated in pregnancy due to severe teratogenicity, necessitating REMS program. Dose adjust for renal impairment (Cr Cl <45 m L/min) and hepatic impairment (Child-Pugh C). Monitor for tumor lysis syndrome, especially in patients with high tumor burden.
Thromboprophylaxis with aspirin or low molecular weight heparin is mandatory due to high VTE risk. Monitor CBC and thyroid function monthly. Contraindicated in pregnancy due to teratogenicity. Pomalidomide requires REMS program enrollment. Dose reduction needed for renal impairment (Cr Cl <45 m L/min).
Pomalidomide is a chemotherapy drug that helps treat multiple myeloma by targeting cancer cells.,Do not take if pregnant or planning to become pregnant; use effective contraception during treatment and for 4 weeks after stopping.,Do not breastfeed while taking pomalidomide.,Report any signs of bleeding, bruising, fever, shortness of breath, or chest pain immediately.,Take exactly as prescribed; do not break, chew, or crush capsules; swallow whole with water.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Avoid live vaccines while on this medication.,Store at room temperature away from moisture and heat.,Keep all appointments for blood tests and other monitoring.,Inform all healthcare providers that you are taking pomalidomide.
Do not become pregnant while taking this drug; use two reliable forms of contraception.,Report any signs of bleeding or bruising, as pomalidomide can cause low platelet counts.,Avoid grapefruit and grapefruit juice as they may increase drug levels.,Take capsules whole, not crushed or chewed, with water.,Do not donate blood during treatment and for 4 weeks after stopping.
No interactions on record
"Dextropropoxyphene, an opioid analgesic, and pomalidomide, an immunomodulatory agent, both pose risks of QT interval prolongation. Co-administration may result in additive QT prolongation, increasing the risk of torsade de pointes, a potentially fatal ventricular arrhythmia. Additionally, dextropropoxyphene may exacerbate the sedative and respiratory depressant effects of pomalidomide, leading to excessive central nervous system depression."
"Concomitant use of pomalidomide and perampanel may result in additive central nervous system (CNS) depression due to their independent sedative properties. Pomalidomide, an immunomodulatory drug, is associated with somnolence and fatigue, while perampanel, an AMPA receptor antagonist, commonly causes dizziness, somnolence, and ataxia. This combination can lead to excessive sedation, impaired cognitive function, and increased risk of falls or accidents, particularly in elderly patients or those with impaired hepatic function."
"The concurrent use of desflurane, a halogenated inhalational anesthetic, with pomalidomide, an immunomodulatory agent, may potentiate the risk of severe hypotension and bradycardia due to additive cardiovascular depression. Desflurane directly depresses myocardial contractility and systemic vascular resistance, while pomalidomide can induce vasodilation and negative chronotropic effects. Clinically, patients may experience profound drops in blood pressure and heart rate, leading to reduced cardiac output and potential end-organ hypoperfusion."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POMALYST vs POMALIDOMIDE, answered by our medical review team.
POMALYST is a Immunomodulatory Agent that works by Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b FGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.. POMALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POMALYST and POMALIDOMIDE depend on the specific clinical indication. These are both Immunomodulatory Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POMALYST is: 4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.. The standard adult dose of POMALIDOMIDE is: 4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POMALYST and POMALIDOMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POMALYST is classified as Category C. Pomalidomide is an immunomodulatory drug (IMiD) structurally related to thalidomide, a known human teratogen. It is contraindicated in pregnancy due to high risk of severe birth de. POMALIDOMIDE is classified as Category C. First trimester: High risk of severe birth defects (e.g., limb anomalies, neural tube defects) due to potent teratogenicity; absolutely contraindicated. Second/third trimester: Ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.